ATE340586T1 - Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände - Google Patents

Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände

Info

Publication number: ATE340586T1
Authority: AT; Austria
Prior art keywords: treatment; pharmaceutical compositions; transplant rejection; autoimmune; inflammatory conditions
Prior art date: 1996-07-30

Application number

AT01131018T

Other languages

English (en)

Inventor

Gerhard Zenke

Hendrik J Schuurman

Barbara Haeberlin

Armin Meinzer

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-30

Filing date

1997-07-29

Publication date

2006-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE340586(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-07-30 Priority claimed from GBGB9615942.1A external-priority patent/GB9615942D0/en

1997-03-18 Priority claimed from GBGB9705684.0A external-priority patent/GB9705684D0/en

1997-07-29 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2006-10-15 Application granted granted Critical

2006-10-15 Publication of ATE340586T1 publication Critical patent/ATE340586T1/de

Links

206010052779 Transplant rejections Diseases 0.000 title abstract 2
230000001363 autoimmune Effects 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
230000004968 inflammatory condition Effects 0.000 title 1
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 abstract 2
108010002350 Interleukin-2 Proteins 0.000 abstract 2
239000003112 inhibitor Substances 0.000 abstract 2
230000035897 transcription Effects 0.000 abstract 2
238000013518 transcription Methods 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
229930105110 Cyclosporin A Natural products 0.000 abstract 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
108010036949 Cyclosporine Proteins 0.000 abstract 1
229960001265 ciclosporin Drugs 0.000 abstract 1
-1 e.g. Chemical compound 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
229960002930 sirolimus Drugs 0.000 abstract 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
239000011885 synergistic combination Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Graft Or Block Polymers (AREA)
Medicinal Preparation (AREA)

AT01131018T 1996-07-30 1997-07-29 Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände ATE340586T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9615942.1A GB9615942D0 (en)	1996-07-30	1996-07-30	Organic compounds
GBGB9705684.0A GB9705684D0 (en)	1997-03-18	1997-03-18	Organic compounds

Publications (1)

Publication Number	Publication Date
ATE340586T1 true ATE340586T1 (de)	2006-10-15

Family

ID=26309775

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT01131018T ATE340586T1 (de)	1996-07-30	1997-07-29	Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
AT97937526T ATE222502T1 (de)	1996-07-30	1997-07-29	Kombinationspräparat mit hemmender wirkung auf die abstossung von transplantaten, autoimmunerkrankungen und entzündungen, welches cyclosporin a und 40-0-(2-hydroxyethyl)-rapamycin enthält

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT97937526T ATE222502T1 (de)	1996-07-30	1997-07-29	Kombinationspräparat mit hemmender wirkung auf die abstossung von transplantaten, autoimmunerkrankungen und entzündungen, welches cyclosporin a und 40-0-(2-hydroxyethyl)-rapamycin enthält

Country Status (14)

Country	Link
US (2)	US6239124B1 (de)
EP (2)	EP0956034B1 (de)
JP (2)	JP3942641B2 (de)
AT (2)	ATE340586T1 (de)
AU (1)	AU730781B2 (de)
CA (1)	CA2261666C (de)
CY (1)	CY2391B1 (de)
DE (2)	DE69736750T2 (de)
DK (2)	DK0956034T3 (de)
ES (2)	ES2270948T3 (de)
NZ (1)	NZ333657A (de)
PT (2)	PT956034E (de)
SI (1)	SI1208847T1 (de)
WO (1)	WO1998004279A1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1033128T4 (da) *	1993-09-28	2012-03-19	Scherer Gmbh R P	Blød gelatinekapselfremstilling
US5858401A (en)	1996-01-22	1999-01-12	Sidmak Laboratories, Inc.	Pharmaceutical composition for cyclosporines
DE69736750T2 (de) *	1996-07-30	2007-08-16	Novartis Ag	Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
US20030199425A1 (en) *	1997-06-27	2003-10-23	Desai Neil P.	Compositions and methods for treatment of hyperplasia
US20030129215A1 (en) *	1998-09-24	2003-07-10	T-Ram, Inc.	Medical devices containing rapamycin analogs
US6890546B2 (en) *	1998-09-24	2005-05-10	Abbott Laboratories	Medical devices containing rapamycin analogs
GB9825632D0 (en) *	1998-11-23	1999-01-13	Novartis Ag	Organic compounds
GB9826882D0 (en)	1998-12-07	1999-01-27	Novartis Ag	Organic compounds
US20020006901A1 (en) *	1999-02-05	2002-01-17	Aldo T. Iacono	Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
WO2000067773A2 (en) *	1999-05-10	2000-11-16	Novartis Ag	Combinations of immunosupressive agents for the treatment or prevention of graft rejections
DK1335928T3 (da) *	2000-11-03	2006-01-02	Univ Manchester	Selektive glukokortikoidreceptoragonister
US20020127263A1 (en) *	2001-02-27	2002-09-12	Wenda Carlyle	Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device
US8741378B1 (en)	2001-06-27	2014-06-03	Advanced Cardiovascular Systems, Inc.	Methods of coating an implantable device
US20040137066A1 (en) *	2001-11-26	2004-07-15	Swaminathan Jayaraman	Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) *	2001-11-26	2003-11-04	Swaminathan Jayaraman	Therapeutic coating for an intravascular implant
US20080145402A1 (en) *	2001-09-10	2008-06-19	Abbott Cardiovascular Systems Inc.	Medical Devices Containing Rapamycin Analogs
US20030054042A1 (en) *	2001-09-14	2003-03-20	Elaine Liversidge	Stabilization of chemical compounds using nanoparticulate formulations
EP1435910B9 (de) *	2001-10-19	2010-02-03	Isotechnika Inc.	Neue cyclosporin-analoge mikroemulsionsvorkonzentrate
WO2003039231A2 (en) *	2001-10-25	2003-05-15	Atherogenics, Inc.	Compounds and methods for treating transplant rejection
US7682387B2 (en) *	2002-04-24	2010-03-23	Biosensors International Group, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) *	2001-11-05	2005-09-06	Sun Biomedical, Ltd.	Drug-delivery endovascular stent and method for treating restenosis
US7109169B2 (en) *	2002-06-28	2006-09-19	Hobai Ion A	Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange
ES2544624T3 (es)	2002-07-16	2015-09-02	Buck Institute For Research On Aging	Producción de policétidos
CN100349627C (zh) *	2002-09-06	2007-11-21	艾博特公司	含有水合抑制剂的医疗装置及其制备方法
SI1539157T1 (sl) *	2002-09-18	2013-11-29	Trustees Of The University Of Pennsylvania	Rapamicin za uporabo pri inhibiciji ali preprečevanju horoidalne neovaskularizacije
US8202530B2 (en) *	2002-09-27	2012-06-19	Advanced Cardiovascular Systems, Inc.	Biocompatible coatings for stents
AR043504A1 (es) *	2003-03-17	2005-08-03	Novartis Ag	Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
US7160867B2 (en) *	2003-05-16	2007-01-09	Isotechnika, Inc.	Rapamycin carbohydrate derivatives
US7994214B2 (en) *	2003-08-29	2011-08-09	Lifecycle Pharma A/S	Solid dispersions comprising tacrolimus
JP2007505932A (ja)	2003-09-18	2007-03-15	マクサイト，インコーポレイテッド	経強膜送達
EP1768662A2 (de)	2004-06-24	2007-04-04	Novartis Vaccines and Diagnostics, Inc.	Immunstimulatoren kleiner moleküle und assays für deren nachweis
US8709469B2 (en)	2004-06-30	2014-04-29	Abbott Cardiovascular Systems Inc.	Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
GB0417852D0 (en)	2004-08-11	2004-09-15	Biotica Tech Ltd	Production of polyketides and other natural products
US8021849B2 (en) *	2004-11-05	2011-09-20	Siemens Healthcare Diagnostics Inc.	Methods and kits for the determination of sirolimus in a sample
CA2597590A1 (en) *	2005-02-09	2006-08-17	Macusight, Inc.	Formulations for ocular treatment
US8663639B2 (en)	2005-02-09	2014-03-04	Santen Pharmaceutical Co., Ltd.	Formulations for treating ocular diseases and conditions
JP2008530145A (ja) *	2005-02-15	2008-08-07	ワイス	経口投与可能なｃｃｉ−７７９製剤
CN103169729A (zh)	2005-02-18	2013-06-26	阿布拉科斯生物科学有限公司	治疗剂的组合和给予方式以及联合治疗
US8735394B2 (en)	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
GB0504994D0 (en)	2005-03-11	2005-04-20	Biotica Tech Ltd	Novel compounds
KR20070116868A (ko)	2005-03-11	2007-12-11	바이오티카 테크놀로지 리미티드	３９데스메톡시라파마이신 및 그 유사체의 의학적 용도
CA2602525A1 (en) *	2005-03-21	2006-09-28	Macusight, Inc.	Drug delivery systems for treatment of diseases or conditions
US7825087B2 (en) *	2005-04-12	2010-11-02	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising cyclosporine
US7189582B2 (en) *	2005-04-27	2007-03-13	Dade Behring Inc.	Compositions and methods for detection of sirolimus
EP1888137A2 (de) *	2005-04-29	2008-02-20	Atrium Medical Corporation	Arzneistoffzuführungsbeschichtung zur verwendung mit einer medizinischen vorrichtung sowie verfahren zur behandlung von gefässverletzung
US8067451B2 (en)	2006-07-18	2011-11-29	Horizon Pharma Usa, Inc.	Methods and medicaments for administration of ibuprofen
US20080021078A1 (en) *	2006-07-18	2008-01-24	Horizon Therapeutics, Inc.	Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) *	2006-07-18	2008-01-24	Horizon Therapeutics, Inc.	Unit dose form for administration of ibuprofen
WO2007012019A2 (en) *	2005-07-18	2007-01-25	Horizon Therapeutics, Inc.	Medicaments containing famotidine and ibuprofen and administration of same
KR101478164B1 (ko) *	2006-02-09	2014-12-31	산텐 세이야꾸 가부시키가이샤	안정한 제제와 그 제조 및 사용 방법
AU2007230964B2 (en)	2006-03-23	2012-07-19	Santen Pharmaceutical Co., Ltd.	Formulations and methods for vascular permeability-related diseases or conditions
US8067033B2 (en)	2007-11-30	2011-11-29	Horizon Pharma Usa, Inc.	Stable compositions of famotidine and ibuprofen
EP2063873A2 (de) *	2006-08-31	2009-06-03	Horizon Therapeutics, Inc.	Nsaid-dosierungseinheitsformulierungen mit h2-rezeptor-antagonisten und verfahren zu ihrer verwendung
US8661630B2 (en)	2008-05-21	2014-03-04	Abbott Cardiovascular Systems Inc.	Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
DE102008060549A1 (de)	2008-12-04	2010-06-10	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
US9393318B2 (en)	2010-03-29	2016-07-19	Abraxis Bioscience, Llc	Methods of treating cancer
KR20130028727A (ko)	2010-03-29	2013-03-19	아브락시스 바이오사이언스, 엘엘씨	치료제의 약물 전달 및 유효성 향상 방법
US8685433B2 (en)	2010-03-31	2014-04-01	Abbott Cardiovascular Systems Inc.	Absorbable coating for implantable device
KR20130088116A (ko)	2010-06-04	2013-08-07	아브락시스 바이오사이언스, 엘엘씨	췌장암의 치료 방법
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
JP5652795B2 (ja) *	2011-01-31	2015-01-14	国立大学法人大阪大学	皮膚疾患を処置するための外用薬およびその製造方法
JP2014516075A (ja)	2011-06-06	2014-07-07	シェブロンフィリップスケミカルカンパニーエルピー	癌治療のためのメタロセン化合物の使用
GB201122305D0 (en)	2011-12-23	2012-02-01	Biotica Tech Ltd	Novel compound
US9220759B2 (en)	2012-02-23	2015-12-29	Abbott Cardiovascular Systems Inc.	Treatment of diabetic patients with a drug eluting stent and adjunctive therapy
US9220584B2 (en)	2012-03-30	2015-12-29	Abbott Cardiovascular Systems Inc.	Treatment of diabetic patients with a stent and locally administered adjunctive therapy
EP2705856A1 (de)	2012-09-07	2014-03-12	Deutsches Zentrum für Neurodegenerative Erkrankungen e.V.	Verbindungen zur Behandlung von neurodegenerativen Erkrankungen
US10172789B2 (en)	2013-01-24	2019-01-08	Palvella Therapeutics Llc	Compositions for transdermal delivery of mTOR inhibitors
CA3059017C (en)	2013-09-24	2021-05-25	Giner Life Sciences, Inc.	System for gas treatment of a cell implant
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en)	2014-08-28	2016-03-03	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016205423A2 (en)	2015-06-15	2016-12-22	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
EP3371590A4 (de) *	2015-11-06	2019-07-10	The Trustees of Columbia University in the City of New York	Exosomale proteinprofilierung zur detektion der herztransplantatabstossung
JP6993003B2 (ja)	2016-11-15	2022-01-13	ガイナーライフサイエンシズ，インク．	皮下インプラントとの使用に適した経皮的ガス拡散装置
CA3078723A1 (en)	2016-11-28	2018-05-31	Nachiappan Chidambaram	Oral testosterone undecanoate therapy
WO2018129364A1 (en)	2017-01-06	2018-07-12	Palvella Therapeutics Llc	Anhydrous compositions of mtor inhibitors and methods of use
CN110603038A (zh)	2017-02-10	2019-12-20	塔姆山治疗公司	雷帕霉素类似物
EP3618916A4 (de)	2017-05-04	2021-04-14	Giner Life Sciences, Inc.	Robuste implantierbare gasabgabevorrichtung und verfahren, systeme und vorrichtungen damit
EP3817743A4 (de)	2018-07-02	2022-07-06	Palvella Therapeutics, Inc.	Wasserfreie zusammensetzungen von mtor-hemmern und verfahren zur verwendung
EP3824296B1 (de)	2018-07-20	2026-04-01	Lipocine Inc.	Orale pharmazeutische zusammensetzung mit testosterontridecanoat und/oder testosterondodecanoat zur behandlung von lebererkrankungen
WO2026099504A1 (en)	2024-11-11	2026-05-15	Tenpoint Therapeutics Limited	Compositions and methods for enriching photoreceptors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4894366A (en)	1984-12-03	1990-01-16	Fujisawa Pharmaceutical Company, Ltd.	Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5100899A (en)	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5286730A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5286731A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
ES2089723T3 (es)	1992-03-27	1996-10-01	American Home Prod	29-demetoxirapamicina para inducir la inmunodepresion.
GB9221220D0 (en) *	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
GB2278780B (en)	1993-05-27	1998-10-14	Sandoz Ltd	Macrolide formulations
GB9601120D0 (en) *	1996-01-19	1996-03-20	Sandoz Ltd	Organic compounds
GB9606452D0 (en)	1996-03-27	1996-06-05	Sandoz Ltd	Organic compounds
DE69736750T2 (de) *	1996-07-30	2007-08-16	Novartis Ag	Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
WO2000067773A2 (en) *	1999-05-10	2000-11-16	Novartis Ag	Combinations of immunosupressive agents for the treatment or prevention of graft rejections

1997
- 1997-07-29 DE DE69736750T patent/DE69736750T2/de not_active Expired - Lifetime
- 1997-07-29 PT PT97937526T patent/PT956034E/pt unknown
- 1997-07-29 CA CA2261666A patent/CA2261666C/en not_active Expired - Lifetime
- 1997-07-29 DE DE69714861T patent/DE69714861T2/de not_active Expired - Lifetime
- 1997-07-29 ES ES01131018T patent/ES2270948T3/es not_active Expired - Lifetime
- 1997-07-29 EP EP97937526A patent/EP0956034B1/de not_active Expired - Lifetime
- 1997-07-29 NZ NZ333657A patent/NZ333657A/xx not_active IP Right Cessation
- 1997-07-29 AU AU40124/97A patent/AU730781B2/en not_active Expired
- 1997-07-29 AT AT01131018T patent/ATE340586T1/de active
- 1997-07-29 PT PT01131018T patent/PT1208847E/pt unknown
- 1997-07-29 SI SI9730756T patent/SI1208847T1/sl unknown
- 1997-07-29 ES ES97937526T patent/ES2182112T3/es not_active Expired - Lifetime
- 1997-07-29 DK DK97937526T patent/DK0956034T3/da active
- 1997-07-29 AT AT97937526T patent/ATE222502T1/de active
- 1997-07-29 DK DK01131018T patent/DK1208847T3/da active
- 1997-07-29 US US09/230,618 patent/US6239124B1/en not_active Expired - Lifetime
- 1997-07-29 JP JP50851398A patent/JP3942641B2/ja not_active Expired - Lifetime
- 1997-07-29 WO PCT/EP1997/004123 patent/WO1998004279A1/en not_active Ceased
- 1997-07-29 EP EP01131018A patent/EP1208847B8/de not_active Expired - Lifetime
2001
- 2001-01-11 US US09/758,301 patent/US6455518B2/en not_active Expired - Lifetime
2003
- 2003-11-28 CY CY0300086A patent/CY2391B1/xx unknown
- 2003-12-08 JP JP2003408898A patent/JP4149905B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US6455518B2 (en)	2002-09-24
EP1208847B8 (de)	2007-02-14
CA2261666C (en)	2010-09-14
EP0956034B1 (de)	2002-08-21
DE69736750T2 (de)	2007-08-16
DK0956034T3 (da)	2002-12-16
HK1023720A1 (en)	2000-09-22
ATE222502T1 (de)	2002-09-15
NZ333657A (en)	2000-05-26
JP2000505806A (ja)	2000-05-16
EP1208847B1 (de)	2006-09-27
JP4149905B2 (ja)	2008-09-17
JP2004210767A (ja)	2004-07-29
US6239124B1 (en)	2001-05-29
ES2270948T3 (es)	2007-04-16
PT1208847E (pt)	2007-07-24
SI1208847T1 (sl)	2007-06-30
US20010008888A1 (en)	2001-07-19
EP1208847A3 (de)	2002-06-12
AU4012497A (en)	1998-02-20
DE69736750D1 (de)	2006-11-09
CA2261666A1 (en)	1998-02-05
JP3942641B2 (ja)	2007-07-11
ES2182112T3 (es)	2003-03-01
EP0956034A1 (de)	1999-11-17
AU730781B2 (en)	2001-03-15
DE69714861D1 (de)	2002-09-26
PT956034E (pt)	2002-12-31
WO1998004279A1 (en)	1998-02-05
DK1208847T3 (da)	2007-01-08
EP1208847A2 (de)	2002-05-29
DE69714861T2 (de)	2003-05-22
CY2391B1 (en)	2004-09-10

Legal Events

Date

Code

Title

Description

2007-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1208847

Country of ref document: EP

Publication	Publication Date	Title
DE69736750D1 (de)	2006-11-09	Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
AU638253B2 (en)	1993-06-24	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
TR199801919T2 (xx)	1999-02-22	Rapamisin t�revlerinin damar hastal�klar� ve yabanc� doku naklinde kullan�m�.
WO2004100868A3 (en)	2005-07-07	Method of treating transplant rejection
MX9101869A (es)	1993-04-01	Ciclosporinas, composicion farmaceutica que las contiene y procedimiento para la produccion de las mismas
ATE190503T1 (de)	2000-04-15	Pharmazeutisches präparat enthaltend glucosidase- und/oder amylasehemmer und einen lipasehemmer
ATE449081T1 (de)	2009-12-15	Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
NZ310767A (en)	2000-11-24	Use of an immunosuppressive or non-immunosuppressive pipecolic acid derivative for treating neurological disorders
MX9306271A (es)	1994-04-29	Carbamatos de rapamicina y composicion farmaceutica que los incluye.
BR0114345A (pt)	2003-08-26	Hidroxiésteres de 7-desmetilrapamicina
ATE424893T1 (de)	2009-03-15	Behandlung und vorbeugung von insulin- produzierende zelltransplantatabstossung
ATE233098T1 (de)	2003-03-15	Kombination eines somatostatin analogs und eines rapamycins
DE602005016729D1 (de)	2009-10-29	Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
ATE474590T1 (de)	2010-08-15	Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
SI0956034T1 (en)	2002-12-31	Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin